Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg downgrades Babcock to 'hold'

(Sharecast News) - Berenberg downgraded Babcock on Thursday to 'hold' from 'buy', pointing to the fact the shares have re-rated since it initiated coverage in 2022 and now adequately price in the benefits of the company's strategic turnaround. "The shares have re-rated by 65% during this time, reflecting the much stronger balance sheet and more focused portfolio," it said.

It noted that Babcock has disclosed a further £90m charge on the Type 31 frigate programme, following the £100m charge disclosed in FY23. The charge stems from higher-than-expected labour costs and the maturing of the design of the vessels, it explained.

"The programme is the last remaining large onerous contract within the group," Berenberg said.

"It represents only circa 5-6% of revenue, although it is an increasing cash drag and concerns that there will further charges on the programme may weigh on sentiment in the medium term, in our view.

"We are also mindful that higher-than-expected labour costs may not be an issue confined to the Rosyth dockyard, and that this could reduce the pace of margin expansion in the remainder of the group."

The bank said it would turn more positive on the shares again on evidence that the Type 31 frigate contract has been de-risked and signs that the pension deficit overhang has been further reduced.

Berenberg lifted its price target on Babcock to 565p from 510p

The bank said its preferred UK defence stocks are buy-rated QinetiQ and Chemring.

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.